TY - JOUR
T1 - A New Target of Dental Pulp-Derived Stem Cell-Based Therapy on Recipient Bone Marrow Niche in Systemic Lupus Erythematosus
AU - Sonoda, Soichiro
AU - Yamaza, Takayoshi
N1 - Funding Information:
This research was funded by Grants-in-Aid for Scientific Research (B) and Early-Career Scientists of the Japan Society for the Promotion of Science (JSPS) (KAKENHI Grant 25293405 to T.Y., KAKENHI Grant JP 19K18945 and JP 21K16932 to S.S.).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Recent advances in mesenchymal stem/stromal cell (MSC) research have led us to con-sider the feasibility of MSC-based therapy for various diseases. Human dental pulp-derived MSCs (hDPSCs) have been identified in the dental pulp tissue of deciduous and permanent teeth, and they exhibit properties with self-renewal and in vitro multipotency. Interestingly, hDPSCs exhibit superior immunosuppressive functions toward immune cells, especially T lymphocytes, both in vitro and in vivo. Recently, hDPSCs have been shown to have potent immunomodulatory functions in treating systemic lupus erythematosus (SLE) in the SLE MRL/lpr mouse model. However, the mechanisms underlying the immunosuppressive efficacy of hDPSCs remain unknown. This review aims to introduce a new target of hDPSC-based therapy on the recipient niche function in SLE.
AB - Recent advances in mesenchymal stem/stromal cell (MSC) research have led us to con-sider the feasibility of MSC-based therapy for various diseases. Human dental pulp-derived MSCs (hDPSCs) have been identified in the dental pulp tissue of deciduous and permanent teeth, and they exhibit properties with self-renewal and in vitro multipotency. Interestingly, hDPSCs exhibit superior immunosuppressive functions toward immune cells, especially T lymphocytes, both in vitro and in vivo. Recently, hDPSCs have been shown to have potent immunomodulatory functions in treating systemic lupus erythematosus (SLE) in the SLE MRL/lpr mouse model. However, the mechanisms underlying the immunosuppressive efficacy of hDPSCs remain unknown. This review aims to introduce a new target of hDPSC-based therapy on the recipient niche function in SLE.
UR - http://www.scopus.com/inward/record.url?scp=85126833029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126833029&partnerID=8YFLogxK
U2 - 10.3390/ijms23073479
DO - 10.3390/ijms23073479
M3 - Review article
C2 - 35408840
AN - SCOPUS:85126833029
SN - 1661-6596
VL - 23
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 7
M1 - 3479
ER -
